Skip to main content
SpringerLink
Log in

Donepezil

In Vascular Dementia

  • Adis Drug Profile
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

  • ▲ Vascular dementia (VaD), caused by stroke or small vessel disease, is the second most common form of dementia after Alzheimer’s disease (AD). Donepezil, an acetylcholinesterase inhibitor currently indicated for use in patients with mild to moderate AD, has recently been evaluated in VaD.

  • ▲ Donepezil 5 or 10mg once daily provided significant improvements in cognition, as determined by the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog), relative to placebo, after 24 weeks in patients with VaD. Pooled data from two, randomised, double-blind, phase III trials showed that the least-squares mean change from baseline score effect size for the ADAS-cog was −1.79 for donepezil 5mg once daily (p < 0.001) and −2.28 for donepezil 10mg once daily (p < 0.001) at 24 weeks (observed cases).

  • ▲ Significant improvement in global functioning occurred with donepezil 5mg once daily compared with placebo (p = 0.003), but not with donepezil 10mg once daily, as measured by the Clinician’s Interview-Based Impression of Change-plus version score (pooled data, observed cases).

  • ▲ Donepezil was generally well tolerated in patients with VaD. Most adverse events were mild to moderate in nature, with diarrhoea and nausea being the most common.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Notes

  1. Use of tradename is for product identification purposes only and does not imply endorsement.

References

  1. Roman GC. Vascular dementia revisited: diagnosis, pathogenesis, treatment, and prevention. Med Clin North Am 2002 May; 86(3): 477–99

    Article  PubMed  Google Scholar 

  2. Pratt RD. Patient populations in clinical trials of the efficacy and tolerability of donepezil in patients with vascular dementia. J Neurol Sci 2002 Nov; 203–204: 57–65

    Article  PubMed  Google Scholar 

  3. Bonner LT, Peskind ER. Pharmacologic treatments of dementia. Med Clin North Am 2002 May; 86(3): 657–74

    Article  PubMed  CAS  Google Scholar 

  4. Bowler JV. Acetylcholinesterase inhibitors for vascular dementia and Alzheimer’s disease combined with cerebrovascular disease. Stroke 2003 Feb; 34(2): 584–6

    Article  PubMed  Google Scholar 

  5. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993 Feb; 43(2): 250–60

    Article  PubMed  CAS  Google Scholar 

  6. Gueyffier F, Boissel J, Boutitie F, et al. Effect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence. The INDANA (INdividual Data ANalysis of Antihypertensive intervention trials) Project Collaborators. Stroke 1997 Dec; 28(12): 2557–62

    Article  PubMed  CAS  Google Scholar 

  7. Pratt RD, Perdomo CA. Donepezil-treated patients with probable vascular dementia demonstrate cognitive benefits. Ann N Y Acad Sci 2002 Nov; 977: 513–22

    Article  PubMed  CAS  Google Scholar 

  8. Amenta F, Di Tullio MA, Tomassoni D. The cholinergic approach for the treatment of vascular dementia: evidence from pre-clinical and clinical studies. Clin Exp Hypertens 2002 Oct–Nov; 24(7–8): 697–713

    Article  PubMed  CAS  Google Scholar 

  9. Dooley M, Lamb H. Donepezil: a review of its use in Alzheimer’s disease. Drugs Aging 2000 Mar; 16(3): 199–226

    Article  PubMed  CAS  Google Scholar 

  10. Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002; 41(10): 719–39

    Article  PubMed  CAS  Google Scholar 

  11. Imbimbo BP. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer’s disease. CNS Drugs 2001; 15(5): 375–90

    Article  PubMed  CAS  Google Scholar 

  12. Rogers S, Farlow M, Doody R, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology 1998 Jan; 50(1): 136–45

    Article  PubMed  CAS  Google Scholar 

  13. Meyer JS, Chowdhury MH, Xu G, et al. Donepezil treatment of vascular dementia. Ann N Y Acad Sci 2002 Nov; 977: 482–6

    Article  PubMed  CAS  Google Scholar 

  14. Li Y, Meyer JS, Haque MA, et al. Feasibility of vascular dementia treatment with cholinesterase inhibitors [letter]. Int J Geriatr Psychiatry 2002 Feb; 17(2): 194–6

    Article  PubMed  Google Scholar 

  15. Sisak E. Donepezil treatment in vascular dementia [abstract]. 2nd International Congress on Vascular Dementia; 2002 Jan 24–27; Salzburg [online]. Available from URL: http://www.kenes.com/abstracts/vas01/73.doc [Accessed 2003 Mar 21]

  16. Mendez MF, Younesi FL, Perryman KM. Use of donepezil for vascular dementia: preliminary clinical experience. J Neuropsychiatry Clin Neurosci 1999 Spring; 11(2): 268–70

    PubMed  CAS  Google Scholar 

  17. Black S, Roman GC, Geldmacher DS, et al. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003; 34(10): 2323–32

    Article  PubMed  CAS  Google Scholar 

  18. Wilkinson D, Doody R, Helme R, et al. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 2003 Aug; 61(4): 479–86

    Article  PubMed  CAS  Google Scholar 

  19. Salloway S, Pratt RD, Perdomo CA, et al. Donepezil-treated patients with vascular dementia demonstrate cognitive and global benefits: results from Study 308, a 24-week, randomized, double-blind, placebo-controlled trial [abstract no. 219]. Neurobiol Aging 2002 Jul–2002 31; 23 Suppl. 1: S57

    Google Scholar 

  20. Salloway SP, Pratt RD, Perdomo CA. Donepezil improves cognition both in patients with probable and those with possible vascular dementia [abstract no. P3114]. Eur J Neurol 2002; 9Suppl. 2: 192

    Google Scholar 

  21. Geldmacher DS, Pratt RD, Perdomo CA. Donepezil slows functional deterioration in patients with vascular dementia [abstract no. SC229]. Eur J Neurol 2002; 9Suppl. 2: 35

    Google Scholar 

  22. Perdomo CA, Pratt RD. A comparison of the effects of donepezil in patients with probable and possible vascular dementia: a combined analysis of two 24-week, randomized, double-blind, placebo-controlled trials [abstract no. P05.115]. Neurology 2002 Apr; 58Suppl. 3: A382

    Google Scholar 

  23. Doody R, Pratt R, Perdomo C, et al. Donepezil-treated patients demonstrate global benefits on the Clinician’s Interview-Based Impression of Change-Plus version: a comparison of Alzheimer’s disease versus vascular dementia [abstract no. S48.002]. Neurology 2003 Mar; 60Suppl. 1: A412

    Google Scholar 

  24. Pratt R, Perdomo C. Population characteristics of patients with VaD [abstract no. PO-45-21]. 12th World Congress of Psychiatry; 2002 Aug 24–29; Yokohama, Japan, 230

  25. Pratt R, Perdomo C, Donepezil 307 and 308 Study Groups. Donepezil is well tolerated in patients with vascular dementia: a comparison of safety and tolerability results from randomized, placebo-controlled clinical trials in vascular dementia patients and Alzheimer’s disease patients [abstract no. 218]. Neurobiol Aging 2002 Jul–Aug; 23Suppl. 1: S57

    Google Scholar 

  26. Black S, Pratt R, Perdomo C, et al. Donepezil is well tolerated in patients with vascular dementia [abstract no. P318]. Stroke 2003 Jan; 34(1): 314

    Article  Google Scholar 

  27. Salloway SP, Pratt RD, Perdomo CA. Donepezil is well tolerated in patients with vascular dementia: a comparison of tolerability in vascular dementia patients and Alzheimer’s disease patients [abstract no. P3122]. Eur J Neurol 2002; 9Suppl. 2: 194

    Google Scholar 

  28. Black S, Pratt R, Perdomo C, et al. Donepezil provides significant benefits on cognition and global function in patients with probable vascular dementia [abstract no. 78]. Stroke 2003 Jan; 34(1): 252

    Article  Google Scholar 

  29. Eisai Inc. U.S. Prescribing information: Aricept® (donepezil hydrochloride tablets) [online]. Available from URL: http://www.aricept.com/pi/aricept_pi.htm [Accessed 2003 Jul 1]

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 1311, New Zealand

    David R. Goldsmith & Lesley J. Scott

Authors
  1. David R. Goldsmith
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lesley J. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David R. Goldsmith.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goldsmith, D.R., Scott, L.J. Donepezil. Drugs Aging 20, 1127–1136 (2003). https://doi.org/10.2165/00002512-200320150-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200320150-00005

Keywords

Search

Navigation